Luckily we're dealing with research not marketing. We don't have to take any particular person's word for what they discover. The tests that are being applied are accepted tests for childhood cognitive function. Anybody can apply them. If the results, when published, are anything like the preliminaries then other research group are going to be all over this with attitudes ranging from shock to complete disbelief. Results as groundbreaking as the preliminaries suggest will be validated or falsified several times over before the end of 12 months... completely independently of either Carrick or Neurotech International.
My personal conclusions (for my own guidance, not yours) from this are:
1) There's nothing to gain for Carrick in releasing false findings when discovery is certain with 12 months of releasing them.
2) We will have validation (or otherwise) as other independent groups attempt to duplicate the results.
3) Therefore, while it's interesting and informative to learn about the background of the various participants, I see no particular cause for alarm in what we know.
4) Your investment in NTI is very far from secure. Averaging down, or leveraging your investments beyond what you're be prepared to lose could be a very painful mistake (witness the Resapp situation when their FDA trial failed).
NTI Price at posting:
24.5¢ Sentiment: Hold Disclosure: Held
